Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases.
Bafaloukos D, Petraki K, Bousmpoukea A, Chatzichristou E, Pieris I, Koutserimpas C, Samonis G. Bafaloukos D, et al. Among authors: petraki k. Vaccines (Basel). 2022 Mar 28;10(4):525. doi: 10.3390/vaccines10040525. Vaccines (Basel). 2022. PMID: 35455274 Free PMC article.
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H, Kalogeras KT, Kronenwett R, Alexopoulou Z, Wirtz RM, Zagouri F, Scopa CD, Gogas H, Petraki K, Christodoulou C, Pavlakis K, Koutras AK, Samantas E, Patsea H, Pectasides D, Bafaloukos D, Fountzilas G. Linardou H, et al. Among authors: petraki k. Anticancer Res. 2015 Jul;35(7):4023-36. Anticancer Res. 2015. PMID: 26124351 Clinical Trial.
Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G. Gogas H, et al. Among authors: petraki k. Clin Breast Cancer. 2010 Jun;10(3):230-7. doi: 10.3816/CBC.2010.n.031. Clin Breast Cancer. 2010. PMID: 20497922 Clinical Trial.
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G. Gogas H, et al. Among authors: petraki k. J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z. J Transl Med. 2016. PMID: 27184134 Free PMC article.
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G. Koutras A, et al. Among authors: petraki k. PLoS One. 2018 Dec 6;13(12):e0207707. doi: 10.1371/journal.pone.0207707. eCollection 2018. PLoS One. 2018. PMID: 30521571 Free PMC article.
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G, Mavroeidis L, Papadopoulou K, Koliou GA, Bamia C, Chatzopoulos K, Samantas E, Mauri D, Efstratiou I, Pectasides D, Makatsoris T, Bafaloukos D, Papakostas P, Papatsibas G, Bombolaki I, Chrisafi S, Kourea HP, Petraki K, Kafiri G, Fountzilas G, Kotoula V. Pentheroudakis G, et al. Among authors: petraki k. Clin Colorectal Cancer. 2019 Dec;18(4):e370-e384. doi: 10.1016/j.clcc.2019.07.007. Epub 2019 Jul 15. Clin Colorectal Cancer. 2019. PMID: 31402291
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T, Kotoula V, Koliou GA, Manousou K, Chrisafi S, Zagouri F, Sotiropoulou M, Pentheroudakis G, Papoudou-Bai A, Christodoulou C, Xepapadakis G, Zografos G, Petraki K, Pazarli E, Koutras A, Kourea HP, Bafaloukos D, Chatzopoulos K, Iliadis A, Markopoulos C, Venizelos V, Arnogiannaki N, Kalogeras KT, Kostopoulos I, Gogas H, Fountzilas G. Koletsa T, et al. Among authors: petraki k. Cancer Immunol Immunother. 2020 Aug;69(8):1549-1564. doi: 10.1007/s00262-020-02557-0. Epub 2020 Apr 18. Cancer Immunol Immunother. 2020. PMID: 32303794 Free PMC article.
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
Zagouri F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, Binas I, Koutras A, Papakostas P, Markopoulos C, Venizelos V, Xepapadakis G, Andrikopoulou Α, Karanikiotis C, Psyrri A, Bafaloukos D, Kosmidis P, Aravantinos G, Res E, Mauri D, Koumarianou A, Petraki K, Tsipoura A, Pectasides D, Gogas H, Fountzilas G. Zagouri F, et al. Among authors: petraki k. Br J Cancer. 2022 Sep;127(4):695-703. doi: 10.1038/s41416-022-01846-y. Epub 2022 May 24. Br J Cancer. 2022. PMID: 35610366 Free PMC article. Clinical Trial.
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
Koumarianou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilas G. Koumarianou A, et al. Among authors: petraki k. Cancer Chemother Pharmacol. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7. Cancer Chemother Pharmacol. 2015. PMID: 25947084
88 results